Press release
BRAF + NSCLC Pipeline Landscape Report 2025: Novel Therapies, Market Outlook, and Clinical Advances
Curious about the latest updates in the BRAF + NSCLC Pipeline? Click here to explore the therapies and trials making headlines @ BRAF + NSCLC Pipeline Outlook Report [https://www.delveinsight.com/sample-request/braf-mutant-non-small-cell-lung-cancer-braf-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the BRAF + NSCLC Pipeline Report
* In June 2025, Pierre Fabre Medicament conducted a phase 2, multicenter, single-arm study with a safety lead-in to investigate the efficacy, safety and pharmacokinetics of encorafenib 450 mg once daily (QD) in combination with binimetinib 45 mg twice daily (BID) (Combo450) in adult Chinese participants with metastatic unresectable stage IV BRAF V600E mutant NSCLC, who are BRAF- and MEK-inhibitor treatment-naive and are either previously untreated or have had one line of prior therapy in metastatic setting.
* DelveInsight's BRAF + NSCLC Pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for BRAF + NSCLC treatment.
* The leading BRAF + NSCLC Companies such as Pierre Fabre Medicament, Xynomic Pharmaceuticals, Inc., Kinnate Biopharma, Revolution Medicines, Inc., Black Diamond Therapeutics , and others.
* Promising BRAF+NSCLC Therapies such as HLX208+HLX10, VS-6766, GSK1120212, Docetaxel, Dabrafenib, Trametinib, encorafenib, binimetinib, MPDL3280A, Vemurafenib, Alectinib and others.
Want to know which companies are leading innovation in BRAF + NSCLC? Dive into the full pipeline insights @ BRAF + NSCLC Clinical Trials Assessment [https://www.delveinsight.com/sample-request/braf-mutant-non-small-cell-lung-cancer-braf-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The BRAF + NSCLC Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The BRAF + NSCLC Pipeline Report also highlights the unmet needs with respect to the BRAF + NSCLC.
BRAF + NSCLC Overview
BRAF mutated lung cancer is a rare form of NSCLC. BRAF mutations have been reported in about 4% of non-small cell lung cancers (NSCLC). They are most common in adenocarcinoma non-small cell lung cancer. BRAF V600E mutations specifically occur in about 1-2% of non-small cell lung cancer patients. Most patients with BRAF V600E tend to have a smoking history.
BRAF-mutant Non-Small Cell Lung Cancer Emerging Drugs
* Encorafenib/Binimetinib: Pierre Fabre Medicament
BRAFTOVI (encorafenib) is a BRAF kinase inhibitor, indicated in combination with MEKTOVI (binimetinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAFV600 mutation. The combination is currently investigated in Metastatic BRAFV600-mutant Non-Small Cell Lung Cancer in Phase II trial with completion expected in March 2025. This combination is indicated and being tested for several other indications.
XP-102: Xynomic Pharmaceuticals, Inc.
XP-102 is a second generation potent and selective pan-RAF inhibitor uniquely binding to the DFG-out conformation, whereas marketed BRAF inhibitors occupy the DFG-in conformation. XP-102 holds potential as an innovative therapy against B-RAF V600 mutated solid tumors including CRC and non-small cell lung cancer and hairy cell leukemia. The drug is currently being investigated for several tumor including non-small cell lung cancer in Phase I/II which is expected to be completed by December 2024.
If you're tracking ongoing BRAF + NSCLC Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ BRAF + NSCLC Treatment Drugs [https://www.delveinsight.com/sample-request/braf-mutant-non-small-cell-lung-cancer-braf-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
BRAF + NSCLC Companies
Pierre Fabre Medicament, Xynomic Pharmaceuticals, Inc., Kinnate Biopharma, Revolution Medicines, Inc., Black Diamond Therapeutics , and others.
The BRAF + NSCLC Pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of BRAF + NSCLC with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for BRAF + NSCLC Treatment.
* BRAF + NSCLC Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* BRAF + NSCLC Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the BRAF + NSCLC market.
BRAF-mutant Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
BRAF + NSCLC Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
From emerging drug candidates to competitive intelligence, the BRAF + NSCLC Pipeline Report covers it all - check it out now @ BRAF + NSCLC Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/braf-mutant-non-small-cell-lung-cancer-braf-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the BRAF + NSCLC Pipeline Report
* Coverage- Global
* BRAF + NSCLC Companies- Pierre Fabre Medicament, Xynomic Pharmaceuticals, Inc., Kinnate Biopharma, Revolution Medicines, Inc., Black Diamond Therapeutics , and others.
* BRAF+NSCLC Therapies- HLX208+HLX10, VS-6766, GSK1120212, Docetaxel, Dabrafenib, Trametinib, encorafenib, binimetinib, MPDL3280A, Vemurafenib, Alectinib and others.
* BRAF + NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* BRAF + NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay ahead in Healthcare Research - discover what's next for the BRAF + NSCLC treatment landscape in this detailed analysis @ BRAF + NSCLC Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/braf-mutant-non-small-cell-lung-cancer-braf-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* BRAF-mutant Non-Small Cell Lung Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* BRAF-mutant Non-Small Cell Lung Cancer- DelveInsight's Analytical Perspective
* Mid Stage Products (Phase II)
* Encorafenib/Binimetinib: Pierre Fabre Medicament
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase I/II)
* XP-102: Xynomic Pharmaceuticals, Inc.
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* BRAF-mutant Non-Small Cell Lung Cancer Key Companies
* BRAF-mutant Non-Small Cell Lung Cancer Key Products
* BRAF-mutant Non-Small Cell Lung Cancer- Unmet Needs
* BRAF-mutant Non-Small Cell Lung Cancer- Market Drivers and Barriers
* BRAF-mutant Non-Small Cell Lung Cancer- Future Perspectives and Conclusion
* BRAF-mutant Non-Small Cell Lung Cancer Analyst Views
* BRAF-mutant Non-Small Cell Lung Cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=braf-nsclc-pipeline-landscape-report-2025-novel-therapies-market-outlook-and-clinical-advances]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release BRAF + NSCLC Pipeline Landscape Report 2025: Novel Therapies, Market Outlook, and Clinical Advances here
News-ID: 4181668 • Views: …
More Releases from ABNewswire
Author Suzanne Wylde Releases Her Book - For a New Mom
"For a New Mom: Encouraging Thoughts & Sketches From a Former New Mom to You" is dedicated to every new mother navigating the first year of motherhood.
Image: https://www.abnewswire.com/upload/2025/10/84f645bdb5aa626120824321d850d133.jpg
Author, coach, and holistic practitioner Suzanne Wylde has announced the release of her deeply personal and uplifting new book, "For a New Mom: Encouraging Thoughts & Sketches From a Former New Mom to You." Available now on Amazon [https://amzn.to/4nfxFn2] and through her official…
Missacc Announces Exclusive Halloween Week Promotion
Missacc is offering a 15% discount on all event dresses.
Missacc [https://www.missacc.com/], a leading online destination for event and formal dresses, today announced the launch of its Halloween Week Sale, offering customers 15% off sitewide for 72 hours only. The sale begins October 30 at 00:00 and concludes November 1 at 23:59, inviting shoppers to discover more than 200+ unique event dress styles designed to elevate every special occasion.
Image: https://www.abnewswire.com/upload/2025/10/a01d6c37fdbb7741944158c4aa17c255.jpg
#SPD11559
The Halloween…
Build, Operate, Scale: Inside Scott Abbott Practical Playbook for Business Growt …
In today's fast-moving world of entrepreneurship, success doesn't come from luck - it comes from structure, discipline, and execution. That's exactly what Scott Abbott delivers through his revolutionary BOS-UP: Build Operate Scale Framework - a model transforming how founders grow smarter, not just faster.
The BOS-UP Framework: Turning Vision Into Action
The BOS-UP: Build Operate Scale Framework isn't just another business concept. It's a proven, step-by-step process that helps leaders build strong…
Stock Strategies and the Top 10 U.S. Stocks by Market Capitalization
Understanding the stock market requires not only tracking price movements but also knowing the best Stock Strategy [https://stockstrategy.net/] that guide profitable trading and investment decisions. In 2025, the U.S. stock market continues to be dominated by technology giants and innovative companies leading global economic growth. Below, we explore effective stock strategies and reveal the top 10 U.S. stocks by market capitalization for 2025.
What Are Stock Strategies?
Stock Strateg [https://stockstrategy.net/]ies are systematic…
More Releases for BRAF
BRAF Metastatic NSCLC Market to Reach USD 2.56 Billion by 2034
The B-Rapidly Accelerated Fibrosarcoma (BRAF) mutation-positive metastatic non-small cell lung cancer (NSCLC) market is emerging as a critical segment within the oncology therapeutics landscape. NSCLC accounts for nearly 85% of all lung cancer cases globally, and while BRAF mutations occur in only 1-3% of patients, they represent a unique subset with distinct biological and clinical features. Over the next decade, the market is poised for robust growth as targeted therapies,…
BRAF-mutant Non-Small Cell Lung Cancer Pipeline: 10+ Companies Advancing Targete …
The treatment landscape for BRAF-mutant Non-Small Cell Lung Cancer (BRAF+ NSCLC), a molecular subtype of NSCLC driven by mutations in the BRAF gene, most commonly the V600E mutation, is rapidly evolving. Traditionally associated with poor prognosis, BRAF+ NSCLC has witnessed significant clinical progress with the development of targeted therapies that inhibit aberrant MAPK pathway signaling. With growing recognition of the heterogeneity and aggressiveness of BRAF-driven tumors, biopharmaceutical companies are increasingly…
BRAF Kinase Inhibitors Market Size Opportunities and Challenges for the Future
The global BRAF Kinase Inhibitors Market was valued at approximately USD 289 million and is projected to reach around USD 618 million by 2032, growing at a compound annual growth rate (CAGR) of 8.8% from 2024 to 2032 .
BRAF Kinase Inhibitors Market Overview
The BRAF Kinase Inhibitors Market is experiencing significant growth, driven by the increasing prevalence of cancers associated with BRAF mutations, such as melanoma, colorectal cancer, and non-small cell…
BRAF Kinase Inhibitors Market to see Huge Growth by 2029
BRAF Kinase Inhibitors Market is anticipated to grow at a significant CAGR during the forecast period. BRAF is a kinase enzyme that helps control cell growth and signalling. This enzyme can be found in a mutated form in some types of cancer, including melanoma and colorectal cancer. Blocking mutated BRAF kinase proteins helps to stop the cancer cells from growing. Some BRAF kinase inhibitors are used to treat cancer. The…
Global BRAF Kinase Inhibitors Market Size, Share and Forecast 2021-2027
The global BRAF kinase inhibitors market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). BRAF is a kinase enzyme that helps control cell growth and signalling. This enzyme can be found in a mutated form in some types of cancer, including melanoma and colorectal cancer. Blocking mutated BRAF kinase proteins helps to stop the cancer cells from growing. Some BRAF kinase inhibitors are used to…
Global BRAF Kinase Inhibitors Market to Witness a Pronounce Growth During 2024
LP INFORMATION offers a latest published report on BRAF Kinase Inhibitors Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report.
According to this study, over the next five years the BRAF Kinase Inhibitors market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019.…
